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a  b  s  t  r  a  c  t
Background: There is no clinically applicable tumor marker for head and neck cancers. Tel-
omerase is detected in approximately 90% of all malignant tumors, it may predict poor
or  favorable outcomes, thus being both a highly attractive biomarker and a target for the
development of molecular-based cancer diagnostics, prognostics, and therapeutics
Aim: Primary aim was to detect a change of telomerase activity before and after curative
treatment.
Materials and Methods: Patients with biopsy proven head and neck squamous cell carcinoma,
stage I-IVB treated with a curative intent, performance status 0–2 and malignancy at one
primary site were included in the study. Telomerase levels were tested in tissue biopsy.
Plasma telomerase levels were tested at baseline, 5 days and at 3 months after treatment
using ELISA.
Results: Raised plasma telomerase activity was seen in all the patients with cancer at base-
line. The mean plasma telomerase level at baseline was 861.4522 ng/ml, at 5 days after
completion of curative treatment was 928.92 ng/ml and at 3 months of follow up was
898.87 ng/ml. The mean tissue biopsy telomerase level was 19768.53 ng/mg. There was a
significant increase in baseline telomerase levels in cancer patients compared to normals
(volunteers) (t = −3.52, p = 0.001).There was a significant increase in plasma levels of telome-
rase  at 3 months compared to baseline values (z = −1.98, p = 0.04). The increase in telomerase
level did not correlate with the response of the treatment.Conclusion: In patients with head and neck squamous cell carcinomas treated with a curative
intent, the change in levels of telomerase correlates neither with the disease status nor with
prognostic factors.© 2019 Greater Po
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.  Background
ead and neck squamous cell carcinomas (HNSCC) are the
ost common malignancy in India1 and the sixth most com-
on  malignancy in the world. HNSCCs commonly present
ith advanced stage, with majority of the patients being
reated with multi-modality therapy consisting of surgery
ollowed by adjuvant radiation therapy with or without
hemotherapy or definitive chemo-radiotherapy with salvage
urgery in non- or poor responders.2,3 The 5 year survival
ates are only 50% with recurrence of disease varying between
0–30% in early stage cancer (stages I and II) and 50–60% in
dvanced stages (stages III and IIV).4 Approximately 35 % of
he patients develop distant metastasis and 30 % develop sec-
nd primary tumors of the upper aero digestive tract, lung, or
sophagus in the later period.5,6
Traditional prognostic factors such as overall stage and
eck metastases at presentation seem to have limited
rediction accuracy and reproducibility.7 In an era where per-
onalized cancer therapy is the need of the hour, biological
arkers have their own clinical significance. Several investi-
ators are currently examining new biological markers. like
hemokine receptors, Human papilloma virus, methylation
arkers, etc. as prognostic and predictive factors in HNSCC
. Biomarkers that are thus able to stratify the risk and enable
linicians to tailor treatment plans and to personalize post-
herapeutic surveillance strategies are highly desirable. Till
ate there is no clinically applicable tumor marker for head
nd neck cancer. Recent studies suggest that telomere attri-
ion, which may be an early event in human carcinogenesis,
nd telomerase activation, which is detected in up to 90% of
alignancies, could be a potential marker of cancer risk and
isease outcome.9
The telomere/telomerase interplay is an important ele-
ent in determining genomic stability and cellular replicative
otential,10 and both telomerase expression/activity and
elomere dysfunction have been extensively investigated in
uman cancer11–13 with most studies indicating that they are
rucial, early events in tumorigenesis often detectable at the
recursor lesion stage.14–18 Telomerase reverse transcriptase
TERT) promoter mutations resulting in increased telomerase
xpression have also been detected in a significant propor-
ion of HNSCC patients.19–21 However, obtaining samples from
ost tumors is invasive and not amenable to serial analyses.
or this reason, investigators have begun to assay telomerase
ctivity in body fluids that might contain tumor cells that have
een released from the tumor site and have begun to com-
are the results with such variables as tumor progression and
umor stage.22,23
Several authors have reported higher TERT mRNA  plasma
evels in cancer patients with respect to those in controls, and
 correlation has been found between circulating TERT lev-
ls and more  severe clinical-pathological features and disease
utcomes9,24,25; thus, circulating TERT could be considered
 noninvasive tool for detecting cancers and monitoring the
ourse of treatment. To our knowledge, the only study that
as investigated the significance of TERT mRNA  plasma lev-
ls in HNSCC patients reported that the values were indeed
ignificantly elevated before surgery and that they decreasediotherapy 2 5 ( 2 0 2 0 ) 28–34 29
significantly two days after surgery.26 Telomerase activity
alone has also been studied in the past, but majority of the
studies were done on populations different from those found
in India. The etiology of the disease in India is completely
different from other countries. Tobacco consumption is more
prevalent in India and the mode of tobacco consumption (e.g.
chewing, snuffing, bidi smoking, reverse smoking) is also dif-
ferent. Also, majority of studies carried out until now have
attempted to photograph telomerase activity at a single point
in time and have been unable to capture the change in telo-
merase activity after a curative treatment. To the best of our
knowledge there is no study that quantifies the change in tel-
omerase levels from baseline to end of the treatment to follow
up.
Therefore, the present study was undertaken to assess
change of telomerase activity by measuring its levels in
plasma of patients with head and neck squamous cell car-
cinoma treated with curative treatment at timely intervals.
2.  Aims  and  objectives
Primary objective was to detect a change of telomerase lev-
els before and after curative treatment in patients diagnosed
with head and neck squamous cell carcinomas. Secondary
objectives were to evaluate the corelation between tissue telo-
merase and blood telomerase activity in the same patient and
to correlate telomerase activity with response to treatment.
3.  Materials  and  methods
Sample size: 101 (calculated with prevalence of peripheral
blood telomerase positive patients being 73%, power 90% with
a precision error of 10% using the study done by LEE BJ et al.27
The patients presenting to the outpatient department of
Vydehi Cancer Centre were enrolled into the study. Inclusion
criteria were biopsy proven HNSCC stage I, II, III, IVA and IVB
treated with a curative intent, performance status 0–2 and
malignancy at one primary site. Patients treated with pal-
liative intent, patients with metastatic disease and patients
treated for any other synchronous malignancy were excluded
from the study.
All the patients underwent thorough history and phys-
ical examination. Biopsy was taken from the primary site.
Biopsy sample was sent for histopathological confirmation of
malignancy and then for tissue telomerase testing. Complete
metastatic work-up was done according to the NCCN 2015
guidelines. Informed consent was taken from all the patients.
The plasma telomerase testing was performed as shown in
Table 1.
For every patient, three samples were collected. Response
assessment was done with clinical examination, Head and
neck CT scan with contrast or direct laryngoscopy or both at
the end of three months using RECIST criteria based on the
requirement.
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Table 1 – Testing timeline.






the time of diagnosis
Definitive chemora-
diation/radiation
Baseline (plasma) Post 5 days of
treatment
(plasma)
At 3 months post radia-
tion/chemoradiation
(plasma)










Tissue telomerase at the
time of diagnosis
y 5Surgery followed by
adjuvant radia-
tion/chemoradiation
Baseline (plasma) Post op da
(plasma)
4.  Telomerase  testing
Plasma from 20 controls (volunteers) was used for the assay.
Biopsy from HNSCC patients were collected before curative
treatment. Plasma from HNSCC patients was collected before
curative treatment and after 5 days (half life of telomerase
20–24 hours) and 3 months after curative treatment. These
plasma samples were used to test the Telomerase activity
using ELISA.
Human TE (Telomerase) ELISA kit from Elabioscience
(Catalog#E-EL-H0164) was used. This kit is based on the sand-
wich  method of ELISA. The microplate provided in this kit has
been pre-coated with an antibody specific to TE. The stan-
dard solution provided in the kit was serially diluted to obtain
the kit recommended concentrations (0 ng/ml, 0.16 ng/ml,
0.31 ng/ml, 0.63 ng/ml, 1.25 ng/ml, 2.5 ng/ml, 5 ng/ml and
10 ng/ml). ELISA was performed on these standard solutions to
obtain the standard curve as per manufacturer’s instructions.
The biopsy samples were weighed and washed with 1X
phosphate buffered saline. The tissue was then frozen using
liquid nitrogen and crushed. It was then transferred to a tube
and 200 l of modified RIPA buffer containing protease and
phosphatase inhibitors was added. The sample was then
sonicated for 5 pluses at 40% amplitude. The samples were
then stored in −80 ◦C overnight. The samples were then spun
down at 10,000 rpm for 10 min. The protein was estimated
using the BCA method. This lysate was used to perform ELISA
as mentioned below.
The biopsy and the plasma samples from the control and
the patients were centrifuged at 1000g for 15 min  at 4 ◦C.
The biopsy samples were then diluted to 1:50 using sample
diluent buffer provided in the kit. The plasma samples were
then diluted to 1:250 using the sample diluent buffer provided
in the kit. 100 l of the sample was added to each well in
duplicates and incubated for 90 min  at 37 ◦C. The sample was
then aspirated. 100 l of biotinylated detection antibody was
added and incubated for 1 h at 37 ◦C. After 1 h, the antibody
was aspirated and the wells were washed thrice using a wash
buffer. After washing, 100 l of HRP conjugate was added
and the plate was incubated for 30 min  at 37 ◦C. The wells
were then washed five times with a wash buffer and 90 l of
substrate was added to each well and incubated for 15 min.
50 l of stop solution was added after 15 min  and then the
plate was read at 450 nm using a plate reader. The opticalAt 3 months post radia-
tion/chemoradiation
(plasma)
Tissue telomerase at the
time of diagnosis
density of the samples was analyzed using the equation
obtained from the standard curve. The results obtained were
represented as ng/mg for biopsy and ng/ml for plasma.
5.  Statistical  analysis
Data was analyzed using SPSS 16 for windows. Frequency
distribution was determined for categorical variables. Kol-
mogorov smirnov tests for normality showed a significant
deviation from normal distribution for telomerase levels.
Hence non-parametric tests were applied. Friedman’s rank
test was used to correlate the levels of telomerase across
various time points. Wilcoxon’s Sign rank test was used to
ascertain group differences at two time points or between tis-
sue and blood telomerase levels. Unpaired T test was used to
compare baseline telomerase levels in cancer patients with
controls.
6.  Results
The patient characteristics, site, staging and treatment details
are shown in Table 2.
Male to female ratio was almost same and there was a
significant increase in the mean telomerase of the biopsy spec-
imen between males and females (p-value = .004), Table 6 for
more  details. Almost three fourth of the total patients used
tobacco in some form and the mean telomerase in the biopsy
specimen was more  for patients who used tobacco but this
increase was not statistically significant (p-value < .02). Major-
ity of the patients had oral cavity as a primary cancer. Lymph
node positivity was seen in 42 patients but the telomerase
levels in the biopsy specimen were statistically insignificant
between node positive and node negative patients. Patients
were more  in T2 and T4 stages and there were more  patients
with locally advanced cancers (n = 64) and less early can-
cers(n = 37). There was no statistical difference between the
mean telomerase levels in the biopsy of early and advanced
stage cancers (p < 0.8) Thirteen patients received surgery as the
sole modality. Eighty eight patients received radiation therapy
either in the form of definitive or adjuvant.
Response evaluation at 3 months is shown in Table 3. Eight
patients did not come back for three month follow up.
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Table 2 – The patient characteristics, site, staging and treatment details are shown in Table 2, along with Mean
Telomerase in tissue.
Gender Number of patients (percentage) Mean telomerase in biopsy (ng/mg)
Male 52 (51.5) 21481.8
Female 49 (48.5) 19768.5
Tobacco Yes 76 (75.2) 21173.3
No 25 (24.8) 19300.1
Site Oral cavity 82 (81.2) 20770.5








N stage Negative 59 (58.4) 20061.4
Positive 42 (41.6) 19269.3
Group stage Stage I 9 (8) 22014.35
Stage II 29 (28.7) 20012.04
Stage III 20 (19.8) 19280.26
Stage IV 42 (41.5) 19509.28
Treatment modality Surgery 13 (12.9%)
Surgery + Adjuvant RT 60 (59.4%)
Definitive chemo radiation 28 (27.7%)
Table 3 – Response evaluation for patients who underwent radiation with or without chemotherapy.
Clinical/radiological response Complete response Partial response Progressive disease Local recurrence Not available
Primary 85 (84.2) 5 (5) 1 (1) 2 (2) 8 (7.9)
Neck nodes 90 (89.1) 3 (3) 8 (7.9)
Table 4 – Baseline blood telomerase comparison between head and neck cancer patients and controls.
Group N Mean Std. deviation Std. error mean
Baseline normal
Normal group (Volunteers) 20 587.49 203.27 45.45383
Experimental group (Cancer patients) 20 807.95 192.28 42.99608






























Std. Deviation 198.352 48
N 101 10
.  Telomerase  levels
he raised plasma telomerase activity was seen in all the
atients with cancer at baseline. The mean plasma telomerase
evel at baseline was 861.4 ng/ml, at 5 days after completion of
urative treatment it was 928.92 ng/ml and at 3 months of fol-
ow up was 898.87 ng/ml. The mean tissue biopsy telomerase
evel was 19768.53 ng/mg.
There was a significant increase in baseline blood tel-
merase levels in cancer patients compared to controls
volunteers) (t = −3.52, p = 0.001) (See Table 4)
There was a significant increase in plasma levels of telome-
ase at 3 months compared to baseline values on Wilcoxon’s
ign rank test (z = −1.98, p = 0.04). However, there was no sig-
ificant change in telomerase levels after day 5 of radiotherapy
ompared to baseline (See Table 7)898.87 19768.53
145.89 15711.31
101 101
The increase in telomerase level did not correlate with the
response of the treatment. Use of tobacco, T stage, and N stage
did not influence the telomerase levels in any way (Table 2).
All patients with high blood telomerase levels at baseline also
had high telomerase levels in the tumor tissue (Table 5).
8.  Discussion
In the process of transformation of a cell from normal state to
malignant, one of the key steps is the immortalization of cells.
Recent evidence indicates that telomerase plays an impor-
tant role in cell immortalization. Telomerase is a highly stable
ribonucleoprotein complex, half-life of which is over 20 h in
vivo. Loss of telomerase activity(TA) has been correlated with
cellular senescence whereas its reactivation may be a pre-
requisite for the development of malignant tumor cells from
32  reports of practical oncology and radiotherapy 2 5 ( 2 0 2 0 ) 28–34














Mean 804.2796 940.7605 910.8210 17951.1807
Std. deviation 168.94648 652.91485 168.37815 12893.35695
N 49 49 49 49
Male
Mean 915.33 917.7543 887.5998 21481.0220
Std. deviation 210.18150 254.34779 121.58290 17927.26954
N 52 52 52 52
Total
Mean 861.4522 928.9157 898.8655 19768.53
Std. deviation 198.34672 487.59594 145.88912 15711.31
N 101 101 101 101










Mean 861.45 928.92 898.87* 19768.53***
Std. deviation 198.352 487.60 145.89 15711.31






P  value 
somatic cells. More  than 85% of human cancer cells are found
to have TA.
Reactivation of telomerase in HNSCC has been observed in
many  reports, however its clinical and prognostic relevance
in these studies has varied.28–31 One of the possible reasons
for this variation was the use of different telomerase activ-
ity assays by different groups. The recent introduction of the
real-time version of measurement of telomerase activity has
made it possible to increase the precision of telomerase activ-
ity determination,32,33 thus increasing the potential interest
of this tumour marker. When real-time PCR or TRAP has
been utilized, weak telomerase expression and activity have
frequently been found in normal upper aero digestive tract
epithelium.34,35 High levels of telomerase expression have
been detected in as much as 75–100 % of HNSCC.36,37 In our
study, all the patients have shown raised telomerase levels
in plasma at baseline. The levels were also detected in vol-
unteers, who were free from cancers. But the rise in cancer
patients was higher and was statistically significant. (t = −3.52,
p = 0.001). Similar results were found by Lee B.J. et al.27 Periph-
eral blood samples were collected from 100 head and neck
squamous cell cancer patients and 20 normal control group.
The difference to the telomerase expression of peripheral
blood mononuclear cells (PBMC) in the normal and cancer
patients was significant. (P < 0.001).
The correlation of telomerase levels with clinical and
histopathological parameters showed conflicting results. In
the same study by Lee B.J. et al.,27 the expression of telome-
rase in PBMCs of patients was significantly correlated with T
classification (P = 0.005), N classification (P = 0.002), and AJCC
stages (P < 0.001). On multivariate analysis, N classification
(P = 0.007), AJCC stages (P = 0.02), and telomerase expression
(P = 0.017) showed independent factors associated with poor
survival. Where, as in an Indian study by Rai A. et al.,38 telo-
merase levels showed no correlation with clinical parameters,
such as sex of the patient, history of adverse habits, site of theaseline vs DAY 5,
 = 0.2
Baseline vs 3




lesion, size of the lesion, lymph node involvement, or over-
all stage of the patient. However, significant correlation with
age of the patient and histopathological grades of malignancy
was observed. In the present study, there was no correlation
between telomerase levels with T stage, N stage and tobacco
use, although at baseline male patients had statistically signif-
icantly increased telomerase levels. Similar results have also
been reported by Fabricius and Koscielny et al.29,39
So far, only one study has answered whether telomerase
can serve as an indicator of disease status in follow up.26 The
study evaluated telomerase activity in peripheral whole blood
from HNSCC patients as a biomarker for diagnosis or detec-
tion of recurrence during follow-up. Among 41 HNSCC patients
who showed positive telomerase activity before surgery, 32
(78.1%) showed a conversion of telomerase activity to negative
after surgery. In follow-up, 6 out of 8 (75%) showed conversion
of telomerase activity from negative to positive after recur-
rence. Telomerase activity was changed to negative in 4 out
of 6 (66%) recurred patients with positive telomerase activ-
ity after second surgery. The rate of telomerase activity in
PBMCs was found to be significantly higher in HNSCC patients
with respect to that in healthy controls and associated with
advanced stage, lymph node metastases, and poor overall sur-
vival (OS).27,40 Two mechanisms have been hypothesized to
explain this finding.26 First, PBMC could be activated by soluble
factors, secreted either by cancer or by the tumor microen-
vironment. Mean serum vascular endothelial growth factor
levels have, indeed, been significantly linked with telomerase
activity in PBMCs in HNSCC patients.41 Alternatively, PBMC
could be activated after tumor antigen processing and cross-
presentation has taken place in draining lymph nodes. In our
study, we did not find any fall in telomerase levels after treat-
ment. On the contrary, we found a rise in 3rd month samples
which was statistically significant and which did not corre-
late with the residual disease status. According to the theory
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esult in multiple malignant foci. This fact may be one of the
easons for persistent high telomerase levels, as three fourth
f the patients in our study were tobacco users with majority of
hem being tobacco chewers. Also the telomerase levels were
ignificantly very high in biopsy tissue samples and plasma
n our patients. Hence, the plasma levels of telomerase mea-
ured quantitatively in patients with HNSCC is a complex
ssue that might warrant further studies. Based on our study
e cannot recommend testing blood telomerase as a marker
or response and prognosis in head and neck squamous cell
arcinomas. The role of telomeres and telomerase in head
nd neck squamous cell carcinoma from pathogenesis to clin-
cal implications has been discussed in detail by Rizzo et al.9
hey felt that our understanding of the complicated telom-
re/telomerase interplay in human cancer remains, in fact, for
he time being incomplete. The negative results of our study
how that telomerase testing in head and neck squamous cell
arcinoma patients is not reliable.
.  Conclusions
n patients with head and neck squamous cell carcinomas
reated with curative intent, the change in levels of telomerase
n peripheral blood correlates neither with the disease status
or with burden of disease post curative treatment. Hence, at
resent quantifying the change in telomerase from blood sam-
les cannot be recommended as a biomarker for response or
rognosis in head and neck cancers.
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